IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

NCT03705403 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

88

Enrollment

OTHER

Sponsor class

Stopped This trial is not transitioning to the Clinical Trial Regulation (CTR) EU No 536/2014.

Conditions

NSCLC Stage IV
Metastatic Disease

Interventions

DRUG: Darleukin
RADIATION: Radiation

Sponsor

Maastricht University Medical Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]